Antiepileptic drugs in schizophrenia:: a review

被引:64
作者
Hosák, L [1 ]
Libiger, J [1 ]
机构
[1] Charles Univ Prague, Sch Med, Dept Psychiat, Hradec Kralove 50005, Czech Republic
关键词
schizophrenia; antiepileptic drugs; gamma-aminobutyric acid; glutamate;
D O I
10.1016/S0924-9338(02)00696-X
中图分类号
R749 [精神病学];
学科分类号
100205 [精神病与精神卫生学];
摘要
The first choice group of psychotropic agents in schizophrenia is neuroleptics. However, this treatment is not effective in all patients and with every symptom. We summarize papers published on the role of antiepileptic drugs in treatment-resistant schizophrenia. We have searched the computer database system MEDLINE for relevant articles including reviews, reports of drug studies and case histories. Antiepileptic drugs can change symptoms of schizophrenia by their action on GABA-ergic neurotransmission or via anti-glutamatergic mechanisms. High doses of adjunctive benzodiazepines reduce positive symptoms, anxiety, and agitation. Carbamazepine is effective in affective symptoms of schizophrenia and influences violent behavior in psychotic patients. Its anti-kindling action may represent a promising treatment strategy for some patients with chronic course of schizophrenia. Valproate treatment leads to a decrease in positive symptoms as well as hostility. Lamotrigine is expected to influence the positive, negative, affective, and cognitive symptoms of schizophrenia. New antiepileptics (e.g., gabapentin, oxcarbazepine, topiramate, vigabatrin) present a promise as potential adjuncts to neuroleptic treatment in resistant symptoms of schizophrenia. (C) 2002 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:371 / 378
页数:8
相关论文
共 43 条
[1]
Attenuation of the neuropsychiatric effects of ketamine with lamotrigine -: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists [J].
Anand, A ;
Charney, DS ;
Oren, DA ;
Berman, RM ;
Hu, XS ;
Cappiello, A ;
Krystal, JH .
ARCHIVES OF GENERAL PSYCHIATRY, 2000, 57 (03) :270-276
[2]
Brewerton T D, 1997, Ann Clin Psychiatry, V9, P31, DOI 10.3109/10401239709147772
[3]
Utilization of valproate: Extent of inpatient use in the New York State Office of Mental Health [J].
Citrome, L ;
Levine, J ;
Allingham, B .
PSYCHIATRIC QUARTERLY, 1998, 69 (04) :283-300
[4]
DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474
[5]
Nefazodone treatment for chronic posttraumatic stress disorder: An open trial [J].
Davis, LL ;
Nugent, AL ;
Murray, J ;
Kramer, GL ;
Petty, F .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (02) :159-164
[6]
A GLUTAMATERGIC HYPOTHESIS OF SCHIZOPHRENIA - RATIONALE FOR PHARMACOTHERAPY WITH GLYCINE [J].
DEUTSCH, SI ;
MASTROPAOLO, J ;
SCHWARTZ, BL ;
ROSSE, RB ;
MORIHISA, JM .
CLINICAL NEUROPHARMACOLOGY, 1989, 12 (01) :1-13
[7]
Combined treatment of schizophrenic psychoses with haloperidol and valproate [J].
Dose, M ;
Hellweg, R ;
Yassouridis, A ;
Theison, M ;
Emrich, HM .
PHARMACOPSYCHIATRY, 1998, 31 (04) :122-125
[8]
Clozapine plus lamotrigine in treatment-resistant schizophrenia [J].
Dursun, SM ;
McIntosh, D .
ARCHIVES OF GENERAL PSYCHIATRY, 1999, 56 (10) :950-950
[9]
Zolpidem-associated hallucinations and serotonin reuptake inhibition: A possible interaction [J].
Elko, CJ ;
Burgess, JL ;
Robertson, WO .
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1998, 36 (03) :195-203
[10]
Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders [J].
Facciolà, G ;
Avenoso, A ;
Scordo, MG ;
Madia, AG ;
Ventimiglia, A ;
Perucca, E ;
Spina, E .
THERAPEUTIC DRUG MONITORING, 1999, 21 (03) :341-345